SDGR - NASDAQ
Schrödinger, Inc.
$14.93
-0.067%Schrödinger, Inc., together with its subsidiaries, provides physics-based software platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on selling its software for drug discovery in the life sciences industry, as well as to customers in materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.
At a Glance
Live SnapshotSchrödinger, Inc. Management Team
Dr. Ramy Farid Ph.D.
Chief Executive Officer, President & Director
Compensation
$1,244,987
Prof. William Goddard III
Co-Founder & Scientific Advisor
Dr. Richard A. Friesner Ph.D.
Co-Founder, Scientific Advisory Chairman and Director
Compensation
$473,400
Ms. Yvonne Tran Esq.
Corporate Secretary, Chief Legal & People Officer
Compensation
$670,101
Dr. Geoffrey Craig Porges MBBS
Executive Vice President & Chief Financial Officer
Compensation
$1,038,380
Mr. Shane Brauner
Executive Vice President & Chief Information Officer
Dr. Robert Lorne Abel Ph.D.
Executive Vice President, Chief Scientific Officer of Platform and Head of Modeling R&D
Compensation
$736,839
Mr. Kenneth Patrick Lorton
Executive Vice President, Chief Technology Officer & Chief Operating Officer of Software
Compensation
$736,839
Dr. Karen Akinsanya Ph.D.
President of Research & Development Therapeutics
Compensation
$931,411
Ms. Jaren Irene Madden
Senior Vice President of Investor Relations & Corporate Affairs
Schrödinger, Inc. Insider Positioning
During the last 12 months, insiders have sold $1.30M worth of SDGR shares, with no buying activity reported.
3 Months
0
0.00
87.5K
1.07M
-1.1M
-$1.07M
3-6 Months
0
0.00
14.7K
192.78K
-193K
-$193K
6-9 Months
0
0.00
1.4K
29.39K
-29K
-$29K
9-12 Months
0
0.00
0
0.00
+0
+$0
Top Buyers
No buying activity
Top Sellers
Farid Ramy
Director, Officer: President & Ceo
$1.10M
Abel Robert Lorne
Officer: See Remarks
$33K
Jain Rachit
Officer: Evp & Cfo
$32K
Dugan Margaret
Officer: Chief Medical Officer
$29K
Lorton Kenneth Patrick
Officer: Evp, Cto & Coo, Software
$28K
Insider Activity Analysis
Net Insider Sentiment
Strong bearish signal with $1.30M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Buy/Sell Ratio
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Recent Trend (3 Months)
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
Insider Participation
5 insider sellers vs. 0 buyers. Widespread selling across multiple insiders may signal concerns.
Insider Activity Insight
Multiple red flags: Heavy selling, numerous sellers, and continued recent selling create a concerning pattern. Investigate fundamental drivers and consider whether company guidance or industry conditions have deteriorated.
SEC Filings
SDGR - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 28, 2026 | April 28, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 24, 2025 | April 24, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 25, 2024 | April 25, 2024 | 2024 | |
DEF 14A DEF 14A N/A | April 27, 2023 | April 27, 2023 | ||
DEF 14A DEF 14A 2022 N/A | April 28, 2022 | June 15, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | April 28, 2021 | June 17, 2021 | 2021 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.